# Adrian V S Hill

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7612716/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 275 papers | 38,420 citations | 3531 90 h-index | 3407 183 g-index |
| 288 all docs | 288 docs citations | 288 times ranked | 40168 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111. | 13.7 | 3,887 |
| 2 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478. | 13.7 | 2,080 |
| 3 | Common West African HLA antigens are associated with protection from severe malaria. Nature, 1991, 352, 595-600. | 27.8 | 1,494 |
| 4 | Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993. | 13.7 | 1,196 |
| 5 | Variation in the TNF-Î± promoter region associated with susceptibility to cerebral malaria. Nature, 1994, 371, 508-511. | 27.8 | 1,169 |
| 6 | Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891. | 13.7 | 979 |
| 7 | Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040. | 30.7 | 900 |
| 8 | Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Medicine, 1998, 4, 397-402. | 30.7 | 640 |
| 9 | Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature, 1992, 360, 434-439. | 27.8 | 638 |
| 10 | Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362. | 13.7 | 540 |
| 11 | Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine, 2004, 10, 1240-1244. | 30.7 | 538 |
| 12 | Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Medicine, 2003, 9, 729-735. | 30.7 | 536 |
| 13 | Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respiratory Medicine,the, 2016, 4, 259-271. | 10.7 | 536 |
| 14 | In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nature Medicine, 2000, 6, 337-342. | 30.7 | 521 |
| 15 | THE IMMUNOGENETICS OF HUMAN INFECTIOUS DISEASES. Annual Review of Immunology, 1998, 16, 593-617. | 21.8 | 513 |
| 16 | Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet, The, 2001, 358, 1927-1934. | 13.7 | 485 |
| 17 | T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278. | 30.7 | 473 |
| 18 | Bayesian refinement of association signals for 14 loci in 3 common diseases. Nature Genetics, 2012, 44, 1294-1301. | 21.4 | 469 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Genetics of susceptibitlity to human infectious disease. Nature Reviews Genetics, 2001, 2, 967-977. | 16.3 | 447 |
| 20 | Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. Clinical Infectious Diseases, 2011, 52, 1-7. | 5.8 | 424 |
| 21 | Human genetic susceptibility to infectious disease. Nature Reviews Genetics, 2012, 13, 175-188. | 16.3 | 413 |
| 22 | Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man. Science Translational Medicine, 2012, 4, 115ra1. | 12.4 | 356 |
| 23 | Vaccines against intracellular infections requiring cellular immunity. Nature, 2000, 406, 793-798. | 27.8 | 334 |
| 24 | Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. Nature Genetics, 2010, 42, 739-741. | 21.4 | 332 |
| 25 | Identifying Recent Adaptations in Large-Scale Genomic Data. Cell, 2013, 152, 703-713. | 28.9 | 325 |
| 26 | Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nature Genetics, 2015, 47, 717-726. | 21.4 | 310 |
| 27 | A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLoS ONE, 2012, 7, e40385. | 2.5 | 301 |
| 28 | A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Science Translational Medicine, 2014, 6, 261ra153. | 12.4 | 297 |
| 29 | A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. New England Journal of Medicine, 2016, 374, 1635-1646. | 27.0 | 295 |
| 30 | Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nature Genetics, 1997, 17, 11-12. | 21.4 | 291 |
| 31 | Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288. | 30.7 | 265 |
| 32 | Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species. Science Translational Medicine, 2012, 4, 115ra2. | 12.4 | 257 |
| 33 | Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nature Communications, 2013, 4, 2836. | 12.8 | 256 |
| 34 | Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet, The, 2021, 397, 1809-1818. | 13.7 | 253 |
| 35 | Aspects of Genetic Susceptibility to Human Infectious Diseases. Annual Review of Genetics, 2006, 40, 469-486. | 7.6 | 244 |
| 36 | The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nature Communications, 2011, 2, 601. | 12.8 | 233 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Severe Malarial Anemia and Cerebral Malaria Are Associated with Different Tumor Necrosis Factor Promoter Alleles. Journal of Infectious Diseases, 1999, 179, 287-290. | 4.0 | 231 |
| 38 | Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4836-4841. | 7.1 | 228 |
| 39 | THEGENOMICS ANDGENETICS OFHUMANINFECTIOUSDISEASESUSCEPTIBILITY. Annual Review of Genomics and Human Genetics, 2001, 2, 373-400. | 6.2 | 227 |
| 40 | Preliminary Assessment of the Efficacy of a T-Cellâ€“Based Influenza Vaccine, MVA-NP+M1, in Humans. Clinical Infectious Diseases, 2012, 55, 19-25. | 5.8 | 224 |
| 41 | Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990. | 13.7 | 214 |
| 42 | Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis. Infection and Immunity, 2001, 69, 681-686. | 2.2 | 213 |
| 43 | Glucose-6-phosphate dehydrogenase deficiency and malaria. Journal of Molecular Medicine, 1998, 76, 581-588. | 3.9 | 210 |
| 44 | ChAd63-MVAâ€“vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. Molecular Therapy, 2012, 20, 2355-2368. | 8.2 | 196 |
| 45 | Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. Journal of Infectious Diseases, 2012, 205, 772-781. | 4.0 | 194 |
| 46 | Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485. | 4.7 | 190 |
| 47 | Viral vectors as vaccine platforms: deployment in sight. Current Opinion in Immunology, 2011, 23, 377-382. | 5.5 | 188 |
| 48 | Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. Molecular Therapy, 2014, 22, 464-475. | 8.2 | 188 |
| 49 | Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2016, 16, 31-42. | 9.1 | 187 |
| 50 | Prime-boost vectored malaria vaccines: Progress and prospects. Hum Vaccin, 2010, 6, 78-83. | 2.4 | 184 |
| 51 | Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infectious Diseases, The, 2020, 20, 816-826. | 9.1 | 182 |
| 52 | Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunological Reviews, 1999, 170, 29-38. | 6.0 | 179 |
| 53 | Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8 <sup>+</sup> T-Cell Responses. Infection and Immunity, 2010, 78, 145-153. | 2.2 | 178 |
| 54 | Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 328-339. | 5.6 | 178 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | A major susceptibility locus for leprosy in India maps to chromosome 10p13. Nature Genetics, 2001, 27, 439-441. | 21.4 | 171 |
| 56 | Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respiratory Medicine,the, 2015, 3, 53-60. | 10.7 | 166 |
| 57 | Vaccines against malaria. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2806-2814. | 4.0 | 165 |
| 58 | Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens. Molecular Therapy, 2014, 22, 668-674. | 8.2 | 165 |
| 59 | Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Scientific Reports, 2017, 7, 46621. | 3.3 | 158 |
| 60 | Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. PLoS ONE, 2012, 7, e31208. | 2.5 | 157 |
| 61 | Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous primeâ€“boost immunisation regimes. Vaccine, 2002, 20, 1039-1045. | 3.8 | 156 |
| 62 | Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. Molecular Therapy, 2011, 19, 2269-2276. | 8.2 | 156 |
| 63 | Heterogeneity of Microsatellite Mutations Within and Between Loci, and Implications for Human Demographic Histories. Genetics, 1998, 148, 1269-1284. | 2.9 | 154 |
| 64 | A protein particle vaccine containing multiple malaria epitopes. Nature Biotechnology, 1997, 15, 1280-1284. | 17.5 | 153 |
| 65 | Calculation of Liverâ€toâ€Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites. Journal of Infectious Diseases, 2005, 191, 619-626. | 4.0 | 152 |
| 66 | Potent Induction of Focused Th1â€Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a RecombinantPlasmodium falciparumMalaria Vaccine. Journal of Infectious Diseases, 1999, 180, 1656-1664. | 4.0 | 148 |
| 67 | Effective induction of high-titer antibodies by viral vector vaccines. Nature Medicine, 2008, 14, 819-821. | 30.7 | 148 |
| 68 | Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers. Journal of Immunology, 2005, 174, 449-455. | 0.8 | 143 |
| 69 | Coated microneedle arrays for transcutaneous delivery of live virus vaccines. Journal of Controlled Release, 2012, 159, 34-42. | 9.9 | 141 |
| 70 | Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass. Science Translational Medicine, 2010, 2, 19ra12. | 12.4 | 139 |
| 71 | Innate Immune Responses to Human Malaria: Heterogeneous Cytokine Responses to Blood-Stage Plasmodium falciparum Correlate with Parasitological and Clinical Outcomes. Journal of Immunology, 2006, 177, 5736-5745. | 0.8 | 138 |
| 72 | Viral vectors as vaccine platforms: from immunogenicity to impact. Current Opinion in Immunology, 2016, 41, 47-54. | 5.5 | 137 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine, 2017, 35, 3780-3788. | 3.8 | 133 |
| 74 | Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology, 2005, 41, 1383-1390. | 7.3 | 125 |
| 75 | Pre-erythrocytic malaria vaccines: towards greater efficacy. Nature Reviews Immunology, 2006, 6, 21-32. | 22.7 | 125 |
| 76 | A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLOS Clinical Trials, 2006, 1, e29. | 3.5 | 124 |
| 77 | Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria. Journal of Immunology, 2005, 175, 5675-5680. | 0.8 | 123 |
| 78 | Genomic modulators of gene expression in human neutrophils. Nature Communications, 2015, 6, 7545. | 12.8 | 120 |
| 79 | Evolution, revolution and heresy in the genetics of infectious disease susceptibility. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 840-849. | 4.0 | 117 |
| 80 | Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania. Nature Communications, 2017, 8, 14946. | 12.8 | 114 |
| 81 | Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Science Translational Medicine, 2015, 7, 286re5. | 12.4 | 113 |
| 82 | CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria. Journal of Immunology, 2011, 187, 1347-1357. | 0.8 | 110 |
| 83 | Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. Journal of Infectious Diseases, 2015, 211, 1076-1086. | 4.0 | 110 |
| 84 | Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosisâ€“infected Individuals. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 724-733. | 5.6 | 107 |
| 85 | A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years. PLoS ONE, 2012, 7, e48322. | 2.5 | 107 |
| 86 | Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses. Molecular Therapy, 2014, 22, 233-238. | 8.2 | 101 |
| 87 | Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial. PLoS ONE, 2008, 3, e1493. | 2.5 | 99 |
| 88 | Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever. Scientific Reports, 2016, 6, 20617. | 3.3 | 98 |
| 89 | Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nature Medicine, 1999, 5, 565-571. | 30.7 | 96 |
| 90 | Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01<sub>B</sub>With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. Journal of Infectious Diseases, 2016, 214, 772-781. | 4.0 | 96 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION FOR MALARIA DIAGNOSIS AND ITS USE IN MALARIA VACCINE CLINICAL TRIALS. American Journal of Tropical Medicine and Hygiene, 2005, 73, 191-198. | 1.4 | 96 |
| 92 | Singleâ€dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. European Journal of Immunology, 2008, 38, 732-741. | 2.9 | 95 |
| 93 | Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Frontiers in Microbiology, 2014, 5, 686. | 3.5 | 95 |
| 94 | High frequencies of circulating IFN-Î³-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restrictedMycobacterium tuberculosis epitope inM. tuberculosis-infected subjects without disease. European Journal of Immunology, 2000, 30, 2713-2721. | 2.9 | 94 |
| 95 | Language continuity despite population replacement in Remote Oceania. Nature Ecology and Evolution, 2018, 2, 731-740. | 7.8 | 91 |
| 96 | Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. European Journal of Immunology, 1996, 26, 1951-1959. | 2.9 | 89 |
| 97 | Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance. Journal of Immunology, 2005, 175, 7264-7273. | 0.8 | 89 |
| 98 | The Induction and Persistence of T Cell IFN-Î³ Responses after Vaccination or Natural Exposure Is Suppressed byPlasmodium falciparum. Journal of Immunology, 2007, 179, 4193-4201. | 0.8 | 88 |
| 99 | Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA). PLoS ONE, 2008, 3, e1638. | 2.5 | 87 |
| 100 | A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine, 2006, 24, 2850-2859. | 3.8 | 86 |
| 101 | Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS ONE, 2011, 6, e22271. | 2.5 | 84 |
| 102 | Genetic susceptibility to invasive Salmonella disease. Nature Reviews Immunology, 2015, 15, 452-463. | 22.7 | 81 |
| 103 | Protection fromPlasmodium berghei infection by priming and boosting Tâ€‰cells to a single class I-restricted epitope with recombinant carriers suitable for human use. European Journal of Immunology, 1998, 28, 4345-4355. | 2.9 | 80 |
| 104 | Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe. PLoS ONE, 2013, 8, e65960. | 2.5 | 80 |
| 105 | AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike proteinâ€“specific T <sub>H</sub> 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211. | 12.4 | 80 |
| 106 | Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. JCI Insight, 2017, 2, . | 5.0 | 78 |
| 107 | Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines. Journal of Immunology, 2010, 185, 7583-7595. | 0.8 | 76 |
| 108 | Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?. Human Vaccines and Immunotherapeutics, 2012, 8, 706-714. | 3.3 | 73 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine, 2005, 23, 857-864. | 3.8 | 72 |
| 110 | Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. American Journal of Tropical Medicine and Hygiene, 2005, 73, 191-8. | 1.4 | 71 |
| 111 | Genetic analysis of hostâ€“parasite coevolution in human malaria. Philosophical Transactions of the Royal Society B: Biological Sciences, 1997, 352, 1317-1325. | 4.0 | 70 |
| 112 | Identification of Targets of CD8+ T Cell Responses to Malaria Liver Stages by Genome-wide Epitope Profiling. PLoS Pathogens, 2013, 9, e1003303. | 4.7 | 70 |
| 113 | Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nature Communications, 2018, 9, 2441. | 12.8 | 69 |
| 114 | Identification of antigens presented by MHC for vaccines against tuberculosis. Npj Vaccines, 2020, 5, 2. | 6.0 | 69 |
| 115 | Microneedle Array Design Determines the Induction of Protective Memory CD8+ T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice. PLoS ONE, 2011, 6, e22442. | 2.5 | 68 |
| 116 | Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial. Molecular Therapy, 2014, 22, 2142-2154. | 8.2 | 68 |
| 117 | Prime and target immunization protects against liver-stage malaria in mice. Science Translational Medicine, 2018, 10, . | 12.4 | 68 |
| 118 | Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA primeâ€“boost immunisation in non-human primates. Vaccine, 2010, 29, 256-265. | 3.8 | 67 |
| 119 | Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Human Vaccines and Immunotherapeutics, 2017, 13, 3020-3032. | 3.3 | 67 |
| 120 | Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice. PLoS ONE, 2013, 8, e67888. | 2.5 | 66 |
| 121 | Genetic linkage of mild malaria to the major histocompatibility complex in Gambian children: study of affected sibling pairs. BMJ: British Medical Journal, 1997, 315, 96-97. | 2.3 | 66 |
| 122 | Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials. PLoS ONE, 2012, 7, e38434. | 2.5 | 66 |
| 123 | Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria. Cell Host and Microbe, 2009, 5, 95-105. | 11.0 | 65 |
| 124 | Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure. PLoS ONE, 2014, 9, e107903. | 2.5 | 65 |
| 125 | Native American gene flow into Polynesia predating Easter Island settlement. Nature, 2020, 583, 572-577. | 27.8 | 64 |
| 126 | Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. PLoS ONE, 2013, 8, e57726. | 2.5 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Association of hepatitis B surface antigen carriage with severe malaria in Gambian children. Nature Medicine, 1995, 1, 374-375. | 30.7 | 62 |
| 128 | Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein. Infection and Immunity, 2006, 74, 2706-2716. | 2.2 | 62 |
| 129 | Consanguinity and susceptibility to infectious diseases in humans. Biology Letters, 2009, 5, 574-576. | 2.3 | 62 |
| 130 | Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity. Journal of Immunology, 2005, 175, 599-606. | 0.8 | 60 |
| 131 | A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 290-295. | 7.1 | 59 |
| 132 | Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. Journal of Infectious Diseases, 2019, 219, 1187-1197. | 4.0 | 59 |
| 133 | Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLoS ONE, 2007, 2, e707. | 2.5 | 57 |
| 134 | The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus. Journal of Immunology, 2011, 187, 2602-2616. | 0.8 | 55 |
| 135 | Cytotoxic T lymphocytes toPlasmodium falciparum epitopes in an area of intense and perennial transmission in Tanzania. European Journal of Immunology, 1996, 26, 773-779. | 2.9 | 54 |
| 136 | PTPN22 and invasive bacterial disease. Nature Genetics, 2006, 38, 499-500. | 21.4 | 54 |
| 137 | Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials. Vaccines, 2018, 6, 50. | 4.4 | 54 |
| 138 | The Immunogenetics of Resistance to Malaria. Proceedings of the Association of American Physicians, 1999, 111, 272-277. | 2.0 | 54 |
| 139 | Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection. Journal of Infectious Diseases, 2013, 208, 340-345. | 4.0 | 53 |
| 140 | Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites. Infection and Immunity, 2014, 82, 1277-1286. | 2.2 | 53 |
| 141 | Progress with viral vectored malaria vaccines: A multi-stage approach involving â€œunnatural immunityâ€• Vaccine, 2015, 33, 7444-7451. | 3.8 | 53 |
| 142 | First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. PLoS ONE, 2018, 13, e0208328. | 2.5 | 53 |
| 143 | Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Molecular Therapy, 2016, 24, 1470-1477. | 8.2 | 52 |
| 144 | Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice. Virology Journal, 2013, 10, 349. | 3.4 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. Npj Vaccines, 2018, 3, 49. | 6.0 | 51 |
| 146 | Direct processing and presentation of antigen from malaria sporozoites by professional antigenâ€presenting cells in the induction of CD8 + Tâ€cell responses. Immunology and Cell Biology, 2005, 83, 307-312. | 2.3 | 49 |
| 147 | Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations. Molecular Therapy, 2014, 22, 1992-2003. | 8.2 | 49 |
| 148 | Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Scientific Reports, 2015, 5, 11820. | 3.3 | 49 |
| 149 | A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS. PLoS ONE, 2014, 9, e115161. | 2.5 | 48 |
| 150 | Estimating the burden of iron deficiency among African children. BMC Medicine, 2020, 18, 31. | 5.5 | 47 |
| 151 | A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine, 2011, 29, 7514-7522. | 3.8 | 46 |
| 152 | Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. Scientific Reports, 2014, 4, 6154. | 3.3 | 46 |
| 153 | Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. PLoS ONE, 2016, 11, e0167951. | 2.5 | 46 |
| 154 | Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis. Science Advances, 2017, 3, e1602096. | 10.3 | 46 |
| 155 | Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1. PLoS ONE, 2011, 6, e20977. | 2.5 | 45 |
| 156 | Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa. PLoS ONE, 2008, 3, e2921. | 2.5 | 45 |
| 157 | Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. European Journal of Immunology, 1995, 25, 1783-1787. | 2.9 | 44 |
| 158 | Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. Biotechnology and Bioengineering, 2012, 109, 719-728. | 3.3 | 44 |
| 159 | Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge. Infection and Immunity, 2007, 75, 5819-5826. | 2.2 | 43 |
| 160 | Fusion of the Mycobacterium tuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates. PLoS ONE, 2012, 7, e33555. | 2.5 | 43 |
| 161 | Analysis of human <scp>B</scp>â€cell responses following <scp>C</scp>h<scp>A</scp>d63â€<scp>MVA MSP</scp>1 and <scp>AMA</scp>1 immunization and controlled malaria infection. Immunology, 2014, 141, 628-644. | 4.4 | 43 |
| 162 | Chronic hepatitis C viral infection subverts vaccineâ€induced Tâ€cell immunity in humans. Hepatology, 2016, 63, 1455-1470. | 7.3 | 43 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | TMEM203 is a binding partner and regulator of STING-mediated inflammatory signaling in macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16479-16488. | 7.1 | 43 |
| 164 | Combining Liver- and Blood-Stage Malaria Viral-Vectored Vaccines: Investigating Mechanisms of CD8+ T Cell Interference. Journal of Immunology, 2011, 187, 3738-3750. | 0.8 | 41 |
| 165 | Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models. Scientific Reports, 2017, 7, 46482. | 3.3 | 41 |
| 166 | Cryopreservation-related loss of antigen-specific IFNÎ³ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy. Vaccine, 2017, 35, 1898-1906. | 3.8 | 40 |
| 167 | A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. PLoS Neglected Tropical Diseases, 2018, 12, e0006870. | 3.0 | 40 |
| 168 | Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. Malaria Journal, 2015, 14, 33. | 2.3 | 39 |
| 169 | Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children. American Journal of Human Genetics, 2016, 98, 1092-1100. | 6.2 | 39 |
| 170 | Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors. Infection and Immunity, 2018, 86, . | 2.2 | 39 |
| 171 | Defence by diversity. Nature, 1999, 398, 668-669. | 27.8 | 38 |
| 172 | RNA and Imidazoquinolines Are Sensed by Distinct TLR7/8 Ectodomain Sites Resulting in Functionally Disparate Signaling Events. Journal of Immunology, 2014, 192, 5963-5973. | 0.8 | 38 |
| 173 | Searching for the human genetic factors standing in the way of universally effective vaccines. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140341. | 4.0 | 38 |
| 174 | Iron Status and Associated Malaria Risk Among African Children. Clinical Infectious Diseases, 2019, 68, 1807-1814. | 5.8 | 38 |
| 175 | Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity. Molecular Therapy, 2012, 20, 1633-1647. | 8.2 | 37 |
| 176 | The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment. Scientific Reports, 2013, 3, 1706. | 3.3 | 36 |
| 177 | Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. Scientific Reports, 2015, 5, 16756. | 3.3 | 36 |
| 178 | Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. Vaccines, 2016, 4, 27. | 4.4 | 35 |
| 179 | Malaria is a cause of iron deficiency in African children. Nature Medicine, 2021, 27, 653-658. | 30.7 | 35 |
| 180 | HIV and HLA: Confusion or complexity?. Nature Medicine, 1996, 2, 395-396. | 30.7 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. Molecular Therapy, 2017, 25, 547-559. | 8.2 | 34 |
| 182 | Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Scientific Reports, 2018, 8, 3390. | 3.3 | 34 |
| 183 | Targeting Antigen to the Surface of EVs Improves the InÂVivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice. Molecular Therapy - Methods and Clinical Development, 2020, 16, 108-125. | 4.1 | 34 |
| 184 | EX VIVO INTERFERON-GAMMA IMMUNE RESPONSE TO THROMBOSPONDIN-RELATED ADHESIVE PROTEIN IN COASTAL KENYANS: LONGEVITY AND RISK OF PLASMODIUM FALCIPARUM INFECTION. American Journal of Tropical Medicine and Hygiene, 2003, 68, 421-430. | 1.4 | 34 |
| 185 | Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain. PLoS ONE, 2014, 9, e100538. | 2.5 | 33 |
| 186 | Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats. Npj Vaccines, 2019, 4, 44. | 6.0 | 31 |
| 187 | Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. Journal of Experimental Medicine, 2020, 217, . | 8.5 | 31 |
| 188 | A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nature Communications, 2021, 12, 4636. | 12.8 | 31 |
| 189 | Paths and timings of the peopling of Polynesia inferred from genomic networks. Nature, 2021, 597, 522-526. | 27.8 | 31 |
| 190 | Induction of CD8+ T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. Vaccine, 2015, 33, 3248-3255. | 3.8 | 30 |
| 191 | Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens. Journal of Immunology, 2018, 201, 1315-1326. | 0.8 | 30 |
| 192 | Recombinant Viral-Vectored Vaccines ExpressingPlasmodium chabaudiAS Apical Membrane Antigen 1: Mechanisms of Vaccine-Induced Blood-Stage Protection. Journal of Immunology, 2012, 188, 5041-5053. | 0.8 | 29 |
| 193 | Risk of nontyphoidal Salmonella bacteraemia in African children is modified by STAT4. Nature Communications, 2018, 9, 1014. | 12.8 | 29 |
| 194 | Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle. Vaccine, 2016, 34, 2296-2298. | 3.8 | 28 |
| 195 | External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance. PLoS ONE, 2014, 9, e97398. | 2.5 | 28 |
| 196 | Identification of hostâ€“pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank. Nature Communications, 2022, 13, 1818. | 12.8 | 28 |
| 197 | A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes. Journal of Experimental Medicine, 2022, 219, . | 8.5 | 28 |
| 198 | Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-Mâ„¢. Vaccine, 2017, 35, 6208-6217. | 3.8 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | A P. falciparum NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages. Frontiers in Cellular and Infection Microbiology, 2019, 9, 96. | 3.9 | 27 |
| 200 | Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. , 2020, 8, e000928. | | 27 |
| 201 | CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria. Frontiers in Immunology, 2018, 9, 1660. | 4.8 | 26 |
| 202 | Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, . | 5.0 | 26 |
| 203 | Vaccines and global health. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2733-2742. | 4.0 | 25 |
| 204 | Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. Journal of Medical Virology, 2001, 65, 664-670. | 5.0 | 24 |
| 205 | Variants in the Mannose-binding Lectin GeneMBL2do not Associate With Sepsis Susceptibility or Survival in a Large European Cohort. Clinical Infectious Diseases, 2015, 61, 695-703. | 5.8 | 24 |
| 206 | Improved method for distinguishing the human source of mosquito blood meals between close family members. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 572-574. | 1.8 | 23 |
| 207 | An integrated expression phenotype mapping approach defines common variants in LEP, ALOX15 and CAPNS1 associated with induction of IL-6. Human Molecular Genetics, 2010, 19, 720-730. | 2.9 | 23 |
| 208 | T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein. PLoS ONE, 2012, 7, e44943. | 2.5 | 23 |
| 209 | Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection. Journal of Immunology, 2013, 190, 1135-1147. | 0.8 | 23 |
| 210 | Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial. Frontiers in Immunology, 2017, 8, 1551. | 4.8 | 23 |
| 211 | Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. Vaccines, 2019, 7, 33. | 4.4 | 23 |
| 212 | Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection. PLoS ONE, 2012, 7, e50447. | 2.5 | 23 |
| 213 | Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. American Journal of Tropical Medicine and Hygiene, 2003, 68, 421-30. | 1.4 | 23 |
| 214 | Induction of CD8 + Tâ€lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus. Immunology and Cell Biology, 2001, 79, 569-575. | 2.3 | 21 |
| 215 | Malaria vaccines: identifying Plasmodium falciparum liver-stage targets. Frontiers in Microbiology, 2015, 6, 965. | 3.5 | 21 |
| 216 | Profiling the host response to malaria vaccination and malaria challenge. Vaccine, 2015, 33, 5316-5320. | 3.8 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. Vaccine, 2015, 33, 1121-1128. | 3.8 | 20 |
| 218 | Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine. Vaccine Journal, 2017, 24, . | 3.1 | 20 |
| 219 | The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia. Science Advances, 2019, 5, eaaw0109. | 10.3 | 20 |
| 220 | Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. Vaccine, 2009, 27, 5589-5598. | 3.8 | 19 |
| 221 | Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. Vaccines, 2019, 7, 40. | 4.4 | 19 |
| 222 | Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses. Scientific Reports, 2018, 8, 15020. | 3.3 | 18 |
| 223 | Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii. PLoS ONE, 2019, 14, e0210407. | 2.5 | 18 |
| 224 | The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8+ T Cells Present in the Liver. Journal of Immunology, 2017, 198, 2006-2016. | 0.8 | 17 |
| 225 | Development of an In Vitro Assay and Demonstration of Plasmodium berghei Liver-Stage Inhibition by TRAP-Specific CD8+ T Cells. PLoS ONE, 2015, 10, e0119880. | 2.5 | 17 |
| 226 | Maintenance of MHC polymorphism. Nature, 1992, 355, 403-403. | 27.8 | 15 |
| 227 | A distinctive peptide binding motif for HLA-DRB1 * 0407, an HLA-DR4 subtype not associated with rheumatoid arthritis. Immunogenetics, 1997, 45, 229-232. | 2.4 | 15 |
| 228 | Workshop report: Malaria vaccine development in Europeâ€“preparing for the future. Vaccine, 2015, 33, 6137-6144. | 3.8 | 15 |
| 229 | An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens. Scientific Reports, 2017, 7, 17011. | 3.3 | 15 |
| 230 | Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. Scientific Reports, 2018, 8, 3896. | 3.3 | 15 |
| 231 | Vaccine innovations for emerging infectious diseasesâ€”a symposium report. Annals of the New York Academy of Sciences, 2020, 1462, 14-26. | 3.8 | 15 |
| 232 | Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Control of Strong and Constitutive Promoters. Frontiers in Cellular and Infection Microbiology, 2020, 10, 270. | 3.9 | 14 |
| 233 | A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. Molecular Therapy, 2022, 30, 2024-2047. | 8.2 | 14 |
| 234 | Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. Vaccine, 2016, 34, 49-55. | 3.8 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria. Scientific Reports, 2017, 7, 7284. | 3.3 | 13 |
| 236 | Immunological considerations for SARS-CoV-2 human challenge studies. Nature Reviews Immunology, 2020, 20, 715-716. | 22.7 | 13 |
| 237 | Ancient DNA reveals five streams of migration into Micronesia and matrilocality in early Pacific seafarers. Science, 2022, 377, 72-79. | 12.6 | 13 |
| 238 | Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors. Vaccine Journal, 2014, 21, 901-903. | 3.1 | 12 |
| 239 | Genetic variation in VAC14 is associated with bacteremia secondary to diverse pathogens in African children. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3601-E3603. | 7.1 | 12 |
| 240 | Distinguishing malaria and influenza: Early clinical features in controlled human experimental infection studies. Travel Medicine and Infectious Disease, 2012, 10, 192-196. | 3.0 | 10 |
| 241 | Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice. Scientific Reports, 2021, 11, 10792. | 3.3 | 10 |
| 242 | Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. , 2021, 9, e003218. | | 10 |
| 243 | Identification of 34 Novel Proinflammatory Proteins in a Genome-Wide Macrophage Functional Screen. PLoS ONE, 2012, 7, e42388. | 2.5 | 9 |
| 244 | The Human Leukocyte Antigen Locus and Rheumatic Heart Disease Susceptibility in South Asians and Europeans. Scientific Reports, 2020, 10, 9004. | 3.3 | 9 |
| 245 | Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule. Scientific Reports, 2020, 10, 5716. | 3.3 | 9 |
| 246 | Rare Variants in MYD88, IRAK4 and IKBKG and Susceptibility to Invasive Pneumococcal Disease: A Population-Based Case-Control Study. PLoS ONE, 2015, 10, e0123532. | 2.5 | 8 |
| 247 | 4-1BBL Enhances CD8+ T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques. PLoS ONE, 2014, 9, e105520. | 2.5 | 7 |
| 248 | Towards a multi-antigen multi-stage malaria vaccine. Malaria Journal, 2014, 13, . | 2.3 | 7 |
| 249 | DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. Diseases (Basel, Switzerland), 2018, 6, 107. | 2.5 | 7 |
| 250 | Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria. Infection and Immunity, 2020, 88, . | 2.2 | 7 |
| 251 | Low immunogenicity of malaria preâ€erythrocytic stages can be overcome by vaccination. EMBO Molecular Medicine, 2021, 13, e13390. | 6.9 | 7 |
| 252 | Imputation Performance in Latin American Populations: Improving Rare Variants Representation With the Inclusion of Native American Genomes. Frontiers in Genetics, 2021, 12, 719791. | 2.3 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P.Âfalciparum Transmission-Blocking Candidate Pfs25 in Humans. Frontiers in Immunology, 2021, 12, 732667. | 4.8 | 6 |
| 254 | Protection from Plasmodium berghei infection by priming and boosting Tâ€‰cells to a single classâ€„I-restricted epitope with recombinant carriers suitable for human use. European Journal of Immunology, 1998, 28, 4345-4355. | 2.9 | 6 |
| 255 | Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria. Frontiers in Immunology, 2022, 13, 795463. | 4.8 | 6 |
| 256 | CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. JCI Insight, 2022, 7, . | 5.0 | 6 |
| 257 | T-cell receptor variable alpha ( TCRAV) polymorphisms in European, Chinese, South American, AfroCaribbean, and Gambian populations. Immunogenetics, 1997, 47, 124-130. | 2.4 | 5 |
| 258 | Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice. PLoS ONE, 2015, 10, e0144515. | 2.5 | 5 |
| 259 | Modeling Combinations of Pre-erythrocytic Plasmodium falciparum Malaria Vaccines. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1254-1259. | 1.4 | 5 |
| 260 | Elevated risk of invasive group A streptococcal disease and host genetic variation in the human leucocyte antigen locus. Genes and Immunity, 2020, 21, 63-70. | 4.1 | 5 |
| 261 | Risk of pneumococcal bacteremia in Kenyan children with glucose-6-phosphate dehydrogenase deficiency. BMC Medicine, 2020, 18, 148. | 5.5 | 4 |
| 262 | Quantitative Association Tests of Immune Responses to Antigens ofMycobacterium Tuberculosis: A Study of Twins in West Africa. Twin Research and Human Genetics, 2004, 7, 578-588. | 1.0 | 3 |
| 263 | Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies. Vaccines, 2021, 9, 262. | 4.4 | 3 |
| 264 | Dissection-independent production ofPlasmodiumsporozoites from whole mosquitoes. Life Science Alliance, 2021, 4, e202101094. | 2.8 | 2 |
| 265 | Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites. PLoS ONE, 2021, 16, e0254498. | 2.5 | 2 |
| 266 | Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation. Scientific Reports, 2021, 11, 20877. | 3.3 | 2 |
| 267 | Genetic susceptibility to multifactorial diseases. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 369-371. | 1.8 | 1 |
| 268 | COVIDâ€19 vaccines for rapid global impact. BJU International, 2021, 127, 137-139. | 2.5 | 1 |
| 269 | Human genetic susceptibility to infectious disease. , 0, . | | 1 |
| 270 | Production of a high purity, Câ€tagged Hepatitis B surface Antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions. Biotechnology and Bioengineering, 0, , . | 3.3 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Clinical Evaluation of New Immunisation Strategies for Enhancing T Cell Responses against M. Tuberculosis. Clinical Science, 2003, 104, 51P-51P. | 0.0 | 0 |
| 272 | Identification of Susceptibility Genes for Tuberculosis in Southern and West Africans Using Family-Based Linkage Analysis and Linkage Disequilibrium Mapping. Clinical Science, 2003, 104, 56P-56P. | 0.0 | 0 |
| 273 | Jenner reborn: a new vaccine institute. Lancet, The, 2009, 373, 445-446. | 13.7 | 0 |
| 274 | Virus-like particle vaccines. , 2022, , 163-176. | | 0 |
| 275 | New Malaria Vaccines: The DNA-MVA Prime-Boost Strategy. , 0, , 87-96. | | 0 |